GEN Exclusives

More »

GEN News Highlights

More »
Aug 10, 2007

Novartis Prolongs Market Exclusivity for High Blood Pressure Medication by Six Months

  • Novartis received an additional six months of market exclusivity for its high blood pressure drug, Diovan. The treatment is indicated for use in adults with high blood pressure and heart failure, as well as heart attack survivors.

    This extension, which takes patent expiration to September 2012, was based on studies conducted in children with high blood pressure. Novartis says that high blood pressure is reported in 5% of children and adolescents in the U.S. An FDA decision on a possible indication to treat children and adolescents with high blood pressure is anticipated by year end.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?